New Data Means Successful Joint Pricing Talks For Orchard’s Libmeldy in Europe

Orchard Therapeutics has secured reimbursement in Ireland, the Netherlands and Belgium nearly a year after the collapse of joint pricing talks between the company and the three countries.

Euros
Ireland, the Netherland and Belgium Agree on Price for Orchard's Costly Gene Therapy • Source: Shutterstock

Additional long-term data from Orchard Therapeutics has convinced Ireland, the Netherlands and Belgium to reimburse the company’s costly gene therapy Libmeldy (atidarsagene autotemcel). The three countries, working together under the BeNeLuxA cross-country initiative, had previously said the drug was too expensive.

“We are pleased to have reached an agreement with the BeNeluxA consortium that enables sustainable access to treatment. The agreement...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography

UK MHRA Helps Sponsors Prepare For ‘World’s First’ Decentralized Manufacturing Framework

 

The UK drug regulator, the MHRA, is set to launch its decentralized manufacturing framework in July, and has issued a series of guidance documents that it believes will help companies and also be of value to other countries that are considering how best to regulate the fledging sector.

Argentina Speeds Up Market Access Process

 

Companies operating in Argentina may get their medicines to the market more quickly thanks to new updates to the medicines authorization system.

What UK’s Clinical Trials Overhaul Means For Orphan Drug Developers

 

The UK government has acknowledged that sponsors of clinical trials for rare diseases face challenges around patient recruitment and trial design, which will be addressed in its clinical trials reform, a lawyer says.